PB0590 - Inflammatory convalescent plasma to treat COVID-19: impact of amotosalen/UVA Pathogen Reduction Technology

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

FC

Fabrice Cognasse

Senior Scientist, Director for Scientific Affairs
Etablissement Français du Sang Auvergne-Rhône-Alpes & INSERM 1059
Decines-Charpieu, Rhone-Alpes, France

Co-Author(s)

HH

Hind Hamzeh-Cognasse

Senior Scientist
SAINBIOSE Laboratory, INSERM, U1059, University of Lyon, Saint-Étienne
Saint-Etienne, Rhone-Alpes, France
AD

Anne Claire Duchez

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes & INSERM U1059
Decines-Charpieu, Rhone-Alpes, France
ME

Marie Ange Eyraud

Technician
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
CA

Charles Antoine Arthaud

Technician
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
AP

Amélie Prier

Technician
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Chapieu, Rhone-Alpes, France
EA

Estelle Audoux

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes & INSERM 1059
Decines-Charpieu, Rhone-Alpes, France
OH

Olivier Hequet

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
BB

Brigitte Bonneaudeau

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
SR

Sandrine Rochette-Eribon

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
FT

Françoise Teyssier

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
VB

Valérie Barlet-Excoffier

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
PC

Patricia Chavarin

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
DL

Dominique Legrand

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
PR

Pascale Richard

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
PM

Pascal Morel

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
PT

Pierre Tiberghien

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France

Background: Blood product in therapeutic transfusion are now commonly acknowledged to present biologically active constituents during processes of preparation. In the midst of worldwide COVI-19 pandemic, preliminary evidence, suggest that convalescent plasma may lessen the severity of COVID-19, particularly concerning patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms.

Aims: This study examined the influence of photochemical pathogen reduction treatment (PRT) using amotosalen‐HCl and UVA light vs untreated control convalescent plasma (n= 72 – paired samples) - cFFP.

Methods: This study investigated the soluble inflammatory factors: sCD40L, IFN-alpha, IFN-beta, IFN-gamma, IL-1 beta, IL-6, IL-8, IL-10, IL-18, TNF-alpha and ex-vivo inflammatory bioactivity on endothelial cells.

Results: We observed that IL-8 concentrations were significantly decreased in cFFP w PRT, whereas IL-18 concentration was increased. We observed after activation with cFFP w PRT and w/o PRT no significant modulation of IL-6 released by endothelial cells. CD54 and CD31 expression in the presence of cFFP (w or w/o PRT) is close to negative controls, even if CD54 and CD31 were significant decreased in presence of cFFP w vs w/o PRT.

Conclusion(s): It appears valuable to carry on investigations, of IL-18 and IL-8, on both the physiopathology of PRT convalescent plasma treated and post marketing clinical trials. Further research, including a careful clinical evaluation of CCP-treated patients, will be required to further define the clinical relevance of these findings.